Cytomegalovirus (HHV-5) Infections (Infectious Disease) - Drugs in Development, 2021

September 2021 | 200 pages | ID: C18A9D3895EDEN
Global Markets Direct

Abstracts

Cytomegalovirus (HHV-5) Infections (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus Infections - Drugs In Development, 2021, provides an overview of the Cytomegalovirus Infections (Infectious Disease) pipeline landscape.Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cytomegalovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cytomegalovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 9, 8, 21, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 9, 11, 2, 6 and 3 molecules, respectively.

Cytomegalovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Cytomegalovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cytomegalovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cytomegalovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cytomegalovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Cytomegalovirus (HHV-5) Infections - Overview
Cytomegalovirus (HHV-5) Infections - Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Drug Profiles
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Number of Products under Development by Universities/Institutes, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Universities/Institutes, 2021
Products under Development by Universities/Institutes, 2021 (Contd..1)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Abhelix LLC, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by AlloVir Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by AlphaVax Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Artemis Therapeutics Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Holdings Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by China Immunotech Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Citranvi Biosciences LLC, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Danuvius BioSciences, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Evrys Bio, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Helocyte Biosciences Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Pharma Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Huinuo Biomedical Technology Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by iCELL Biotechnology Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Karyopharm Therapeutics Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Memo Therapeutics AG, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Nobelpharma Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Okogen Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Orgenesis Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Prosit Sole Biotechnology (Beijing) Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Provention Bio Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Shanxi Kangbao Biological Product Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by SL VaxiGen Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by SpyBiotech Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Stadius Biopharma LLC, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Synklino ApS, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Vichem Chemie Research Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Viramatix Sdn Bhd, 2021
Cytomegalovirus (HHV-5) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021
Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021
Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..1)
Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..2)
Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..3)
Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..4)
Cytomegalovirus (HHV-5) Infections - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021